11. Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme. (3rd October 2022) Authors: De Caterina, R; Unverdorben, M; Lee, B C; Yamashita, T; Lin, W S; Wang, C C; Pecen, L; Borrow, A; Chen, C; Kirchhof, P Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS). (25th November 2020) Authors: Chao, T.F; Kirchhof, P; Koretsune, Y; Yamashita, T; Unverdorben, M; Reimitz, P; Chen, C; De Caterina, R Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program. (14th October 2021) Authors: Dinshaw, L; Chen, C; De Caterina, R; Jiang, W; Kim, Y.-H; Koretsune, Y; Morrone, D; Pecen, L; Reimitz, P.-E; Wang, C.-C; Yamashita, T; Unverdorben, M; Kirchhof, P Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. The real-world effectiveness and safety of edoxaban treatment in 27, 333 Global ETNA-AF programme patients with and without a history of heart failure. (3rd October 2022) Authors: Siller-Matula, J; Unverdorben, M; Wang, C C; Koretsune, Y; Pecen, L; Borrow, A; Chen, C; Kirchhof, P; De Caterina, R Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Two-year effectiveness and safety outcomes in 27, 333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme. (3rd October 2022) Authors: Russo, V; Wang, C C; Unverdorben, M; Yamashita, T; Pecen, L; Borrow, A; Chen, C; Kirchhof, P; De Caterina, R Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗